Whilst this data is promising in terms of efficacy for weight reduction and glycaemic control, the full safety and tolerability profile, including long-term GI effects, has not yet been established
Reformulation Strategies Under Investigation The original MK-677 formulation (oral capsule, immediate release) presents known limitations: once-daily dosing produces supraphysiologic GH peaks in the first 2-3 hours followed by gradual decline, and systemic exposure drives appetite and glucose effects 1
What the evidence actually says in 2026: Suicide risk: FDA reviewed the data and on Jan 13, 2026 requested removal of the suicidal ideation warning from GLP-1 labels no increased risk found
With the expected growing number of GLP-1 users, this could have a potential impact of USD 55-90 bn on grocery spending in the US in 2030
At the highest dose tested, some participants lost nearly a quarter of their body weight
This ensures faster absorption and quicker results compared to traditional oral supplements or medications